Rhode Island 2024 Regular Session

Rhode Island Senate Bill S2982

Introduced

4/16/24

Refer

4/16/24

Report Pass

6/4/24

Engrossed

6/6/24

Enrolled

6/11/24

Passed

6/17/24

Caption

Replaces the term "the drug naloxone" with the term "opioid antagonist" in chapters regulating life insurance policies and group life insurance policies.

Impact

If enacted, S2982 will significantly impact policies governing life insurance applications and the overall treatment of individuals who require opioid antagonists. The bill explicitly prohibits life insurance companies from denying applications based solely on the presence of a naloxone prescription or similar opioid antagonists. This change aims to enhance access to life insurance for individuals at risk of opioid-related health issues, thereby aligning insurance practices with public health goals and providing essential protections for these individuals.

Summary

Senate Bill S2982, presented by Senator Roger Picard, seeks to amend Rhode Island's existing laws regarding life insurance policies and reserves. The bill specifically changes the language in the state's insurance statutes from referring to 'naloxone' to 'opioid antagonist.' This adjustment not only addresses the increasing awareness of opioid-related matters but also broadens the definition to encompass a wider class of medications used for opioid overdose prevention. By doing so, the bill aims to reinforce non-discriminatory practices in insurance coverage associated with individuals who have prescriptions for these drugs.

Contention

While the bill's intention is widely regarded as beneficial, it may invoke contention regarding its implications on insurance company underwriting standards. Some stakeholders may argue that the legislation could inadvertently lead to increased risks for insurers if coverage is extended without adequate actuarial justification. Critics might express concerns over the potential financial repercussions on insurance markets, as well as whether the protective measures adequately balance the risks of insuring individuals with opioid prescriptions. Furthermore, debate may arise over the general acceptance of opioid antagonists in the context of insurance risk assessment.

Latest S2982 Activity

Companion Bills

No companion bills found.

Similar Bills

RI H7719

Replaces the term "the drug naloxone" with the term "opioid antagonist" in chapters regulating life insurance policies and group life insurance policies.

CA AB915

Pupil health: drug education: opioid overdose training program.

MI SB1157

Health: pharmaceuticals; authority of certain physicians issuing standing orders; provide for. Amends secs. 9204 & 17744e of 1978 PA 368 (MCL 333.9204 & 333.17744e).

CA AB1915

Pupil health: drug education: opioid overdose training program.

CA AB1320

California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

IA HF595

A bill for an act relating to controlled substances including the manufacture, delivery, or possession of a controlled substance including fentanyl; the manufacture of a controlled substance in the presence of a minor; conspiracy to manufacture for delivery or delivery or intent or conspiracy to deliver a controlled substance to a minor; receipt, provision, and administration of opioid antagonists, including by secondary distributors; providing for immunity; and providing penalties. (Formerly HSB 104.) Effective date: 07/01/2023.

HI SB2030

Relating To Prescription Drugs.

ND HB1447

Funds under management of the state investment board, opioid antagonist prescription, distribution, possession, or use, and the funding of the opioid treatment and prevention program; to provide an appropriation; to provide for a transfer; to provide for application; and to declare an emergency.